350 rub
Journal Technologies of Living Systems №7 for 2009 г.
Article in number:
DEVELOPING OF NEW APPROACHES TO EVALUATION AT THE MOLECULAR LEVEL THE EFFECTIVENESS OF TREATMENT OF PSORIASIS
Keywords: psoriasis gene expression RТ-PCR AР-1 interference currents PUVA-therapy
Authors:
E.S. Piruzian, I.M. Korsunskaya, V.V. Sobolev, R.M. Abdeev, A.L. Piruzyan, D.N. Serov, N.L. Starodubtseva, A.M. Elkin, S.A. Ilyina, A.G. Soboleva, S.A. Bruskin
Abstract:
We have performed a quantitive analysis of expression of JUND, JUNB, C-JUN, C-FOS, FRA-1 и FRA-2 genes in psoriatic lesioned skin. These genes are the components of AP-1 transcription factor. A comparative analysis of expression profiles of these genes in psoriatic lesioned and visually non-lesioned skin of 10 pathients before and after interferential therapy and 4 pathients before and after PUVA therapy was per-formed. We have shown experimentally, that in psoriatiс lesioned skin of non-treated pathients expression of FRA-1 is significantly up-regulated compared to visually non-lesioned skin. The level of expression was dramatically reduced after the treatment. We suppose that the high expression level of FRA-1 could be used as a marker of the pathology of psoriatic process. We have also found out, that of JUND, JUNB, C-JUN, C-FOS, FRA-2 gene expression in psoriatic lesioned skin compared to visually non-lesioned skin was reduced. In our paper we have shown that after interferential therapy of psoriatic lesioned skin and also after PUVA therapy expression level of all analysed genes have changed dramatically. Gene expression of JUND, JUNB, C-JUN, C-FOS, FRA-2 in psoriatic lesioned skin compared to visually non-lesioned skin after interferential therapy of psoriatic lesioned skin and also after PUVA therapy was increased. We suppose that such significant gene expression change in psoriatic lesioned skin after therapy could prove the correctness of chosing this genes (compo-nents of transcriptional factor AP-1) as possible candidate genes for the development of psoriatic process. Among analysed genes, coding the components of AP-1 complex, FRA-1 is stably up-expressed. Futhermore, the expression change of this gene before and after the treatment has shown a clear tendency to mRNA reduction after a successful treatment, what correlated with the improvement of pathienthood. It is supposed that transcriptional activity of FRA-1 could be a kind of marker of treatment efficiency at molecular level.
Pages: 16-23
References
  1. Peters B., Weissman F., Gill M. Pathophysiology and treatment of psoriasis.// Am J Health Syst Pharm. 2001. V.57,N.7. P.645-59.
  2. Nickoloff B., Nestle F. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities // J Clin Invest. 2004. V.113. No.12. P.1664-75.
  3. Schon M., Boehncke W. Psoriasis // N Engl J Med. 2005. V. 352. No.18. P.1899 - 912.
  4. Bowcock A., Krueger J. Getting under the skin: the immunogenetics of psoriasis //Nature Reviews Immunology. 2005. V. 5. N. 10. P.699 -711.
  5. Lowes M., Bowcock A., Krueger J. Pathogenesis and therapy of psoriasis // Nature. 2007. V. 445. Nо. 7130. P.866 -73.
  6. Swanbeck G., Inerot A., Martinsson T., Enerback C., Enlund F., Samuelsson L., Yhr M., Wahlstrom J.Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands // Br J Dermatol. 1997. V.137. Nо. 6. P. 939-42.
  7. Samuelsson L., Enlund F., Torinsson A., Yhr M., Inerot A., Enerback C., Wahlstrom J., Swanbeck G., Martinsson T. A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach // Hum Genet. 1999. V.105. Nо. 6. P. 523 -9.
  8. Prinz J. Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-reactive T cells - An immunological view of the pathophysiology of psoriasis // Clin Exp Dermatol. 2001. V.26. Nо. 4. P. 326 -32.
  9. Bowcock A., Cookson W. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis // Hum Mol Genet. 2004. V.13. Spec No 1. P. R43 -55.
  10. Barker J. Genetic aspects of psoriasis // Clin Exp Dermatol. 2001. V.26. Nо. 4. P.321 -5.
  11. Oestreicher J., Walters I., Kikuchi T. [et al.] Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling // Pharmacogenomics 2001. V.1. P.272 -87.
  12. Bowcock A., Shannon W., Du F. et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies // Hum Mol Genet 2001. V.10. P.1793-805.
  13. Zhou X., Krueger J., Kao M. et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucteotide array // Physiol Genomics 2003. V.13. P.69-78.
  14. Quekenborn-Trinquet V., Fogel P., Aldana-Jammayrac O. [et al.] Gene expression profiles in psoriasis: analysis of impact of body site location and clinical severity // Br J Dermatol 2005. V.152. P.489-504.
  15. Kulski J., Kenworthy W., Bellgard M. et al. Gene expression profiling of Japanese psoriatic skin reveals an increased activity in molecular stress and immune response signals // J.Mol. Med. 2005. V.85. P. 964-975.
  16. Yao Y., Richman L.,Morehouse C. et al. Type I Interferon: Potential Therapeutic Target for Psoriasis - // PLoS One. 2008. V. 3. Nо. 7.e2737. P.1-14.
  17. Пирузян Э.С., Никольская Т.А., Абдеев Р.М. и др. Компоненты транскрипционного фактора AP-1 как гены-кандидаты, участвующие в развитии псориатического процесса // Молекулярная биология. 2007. Т. 41. С. 1069-1080.
  18. Пирузян Э.С., Ишкин А.А., Никольская Т.А. и др. Сравнительный анализ молекулярно-генетических процессов при патогенезе псориаза и болезни Крона // Молекулярная биология. 2009. Т. 43. № 1. С. 175 - 179.
  19. Турпаев К.Т. Роль фактора транскрипции АР-1 в интеграции внутриклеточных сигнальных путей // Молекулярная биология 2006. T.40. №6. С. 945 -961.
  20. Lee, W., Mitchell P. Purified transcription factor AP-1 interacts with TPA inducible enhancer elements // Cell 1987. V.49. Nо.6. P. 741 -52.
  21. Chen L., Glover N. Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA // Nature 1998. V. 392. Nо. 6671. P. 42 -8.
  22. Angel P., Karin M.The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation // Biochim Biophys Acta 1991. V. 1072. Nо. 2 - 3. P. 129 - 57
  23. 23.Sonkoly E., Wei T., Janson P., Sääf A., Lundeberg L., Tengvall-Linder M., Norstedt G., Alenius H., Homey B., Scheynius A., Ståhle M., Pivarcsi A. MicroRNAs: novel regulators involved in the pathogenesis of Psoriasis - // PLoS ONE 2007. V. 2. Nо.7. P. 610.
  24. Livak K., Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method // Methods. 2001. V. 25. No. 4. P. 402 - 8.
  25. Wolf B., Dertinger.H., Wolf G. Die Wir­kung von Interferenzstrom auf Psoriasis vulgaris // Aktuelle dermatologie 2006. V.22. P. 94-97.
  26. Philipp A., Wolf G., Rzany B., Dertinger.H., Jung E. Interferential current in palmar psoriaris // European Journal of Dermatology 2002. V. 9. P. 98 - 101.
  27. Adrian R.Photochemotherapy in psoriasis and other skin diseases // Am Fam Physician. 1981. V. 23. No. 5. P. 95 - 100.
  28. Wolf P., Nghiem D., Walterscheid J., Byrne S., Matsumura Y., Bucana C., Ananthaswamy H., Ullrich S.Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis // Am J Pathol 2006. V.169, No.3. P. 795 - 805.
  29. Grundmann-Kollmann M., Podda M., Brдutigam L., Hardt-Weinelt K., Ludwig R., Geisslinger G., Kaufmann R., Tegeder I.Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration // Br J Clin Pharmacol. 2002. V. 54. No. 5. P. 535 - 9.
  30. Zenz R., Eferl R., Kenner L.et al.Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins // Nature 2005. V. 437. P. 369 - 375.
  31. Vandal K., Rouleau P., Boivin A., Ryckman C., Talbot M., Tessier P.A. Blockade of S100A8 and S100A9 suppresses neutrophil migration in response to lipopolysaccharide // J. Immunol. 2003. V. 171. P. 2602 - 2609.
  32. Bantel H., Schmitz M., Raible A. et al. Critical role of NF-kappaB and stress-activated protein kinases in steroid unresponsiveness//FASEB J. 2002. V. 16. No. 13. P. 1832-4.
  33. Gonsky R., Deem R., Hughes C. et al.Activation of the CD2 pathway in lamina propria T cells up-regulates functionally active AP-1 binding to the IL-2 promoter, resulting in messenger RNA transcription and IL-2 secretion //J. Immunol. 1998. V. 160. No. 10. P. 4914 - 22.